©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2025; 17(4): 102978
Published online Apr 27, 2025. doi: 10.4254/wjh.v17.i4.102978
Published online Apr 27, 2025. doi: 10.4254/wjh.v17.i4.102978
Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?
Luciana Agoglia, Department of Internal Medicine, School of Medicine, Section of Gastroen
Maria Chiara Chindamo, Cristiane Villela-Nogueira, Department of Internal Medicine, School of Medicine and Hepatology Division, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Brazil
Co-first authors: Luciana Agoglia and Maria Chiara Chindamo.
Author contributions: Agoglia L and Chindamo MC contributed equally as co-first authors; Agoglia L performed a critical literature review, prepared the manuscript, and wrote it; Chindamo MC and Villela-Nogueira C provided input in writing the paper and performed a critical review of the manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Cristiane Villela-Nogueira, MD, PhD, Professor, Department of Internal Medicine, School of Medicine and Hepatology Division, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco 255 room 9E16, Rio de Janeiro 21941-913, Brazil. crisvillela@hucff.ufrj.br
Received: November 5, 2024
Revised: March 8, 2025
Accepted: March 27, 2025
Published online: April 27, 2025
Processing time: 172 Days and 19 Hours
Revised: March 8, 2025
Accepted: March 27, 2025
Published online: April 27, 2025
Processing time: 172 Days and 19 Hours
Core Tip
Core Tip: The prevalence of metabolic syndrome and steatosis is higher in patients with psoriasis; the concept of the hepato-dermal axis shows common inflammatory pathways between steatotic liver and psoriatic skin. The interplay between metabolic dysfunction and the use of methotrexate in patients with psoriasis might raise questions about whether a new subcategory under the umbrella of steatotic liver disease might be considered.